OakChart

Psyence Biomedical Ltd

PBMHealthcare·Biotechnology·Canada·Nano·NASD·Nov 11 • 1:12 PM ET

3.10+0.07 (2.31%)
2026-11-11 19:21 CET
Market cap
11.56 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-6.94 USD m
Free cash flow, TTM
-8.14 USD m
EPS diluted, TTM
-12.56
P/E
-
Compare

Price

PBM against its 20, 50 and 200-day averages
2050200
2.505.007.5010.0012.50449K898KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PBMclose 3.1020-day 3.5750-day 4.63200-day 3.933.10

83.4% under the 52-week high of 18.62 on 13 Nov 2025. 52-week low 1.92 on 23 Feb 2026. Last 15 sessions, 76.8% high to low

Profile

PBM
52-week range, 7% of the way up
1.9218.62

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on February 25, 2021 and is headquartered in Toronto, Canada.

Employees12
IPODec 10, 2021
Beta1.73
ATR, 14d0.40
Rel volume0.26
Short float1.80%
Insider own72.19%
Inst own13.24%

Snapshot

6 groups

Valuation

Index-
Market Cap11.83M
Enterprise Value4.63M
Income-
Sales-
Book/sh39.62
Cash/sh1.89
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPODec 10, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.08
P/C1.64
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.09
Current Ratio8.09
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-105.54%
Sales Y/Y TTM-
EPS Q/Q-23614.18%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own72.19%
Insider Trans0.00%
Inst Own13.24%
Inst Trans7.25%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-13.16%
SMA50-33.06%
SMA200-21.19%
Trades-

Technical

Shs Outstand3.81M
Shs Float1.06M
Short Float1.80%
Short Ratio0.25
Short Interest0.02M
52W High18.62 -83.35%
52W Low1.92 61.46%
Volatility9.27% 12.33%
ATR (14)0.40
RSI (14)36.08
Beta1.73
Rel Volume0.26
Avg Volume76.61K
Volume12,176

Performance

Perf Week-2.52%
Perf Month-31.87%
Perf Quarter-12.92%
Perf Half Y-39.92%
Perf YTD-34.17%
Perf Year-81.42%
Perf 3Y-99.99%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close3.03
Price3.10
Change %2.31%

Peers

Mkt cap
TickerCompanyMkt cap
CMNDClearmind Medicine Inc2.49M
GHRSGH Research PLC1.32B
DRUGBright Minds Biosciences Inc216.57M
ENVBEnveric Biosciences Inc6.78M
SILOSILO Pharma Inc2.87M
RLMDRelmada Therapeutics Inc474.68M
VTGNVistagen Therapeutics Inc8.25M
ANROAlto Neuroscience Inc1.16B
KTTAPasithea Therapeutics Corp18.37M
SPRCSciSparc Ltd0.80M

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M

News

latest 14 of 200
  • Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met (GlobeNewswire) +6.60%
  • Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine (GlobeNewswire)
  • Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation (GlobeNewswire)
  • Psyence BioMed Agrees Up to $5 Million PsyLabs Investment and Forms Texas Ibogaine Unit (InvestorsHub)
  • Psyence BioMed Announces Strategic Ibogaine Investment (GlobeNewswire)
  • Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development (GlobeNewswire) +11.11%
  • Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development (GlobeNewswire) +23.82% -8.28%
  • Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -10.87%
  • Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder (GlobeNewswire)
  • Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source (GlobeNewswire) +48.68%
  • Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine (GlobeNewswire) +29.47%
  • Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement (TMX Newsfile) +5.73%
  • Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual1.5741.533-49.0611.397-12.56
Period20212022202320242025
EPS, quarterly1.590.6470.4480.1680.43-0.013-0.5260.043-3.178
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q2 '24Q2 '25
Sales, annual00000
Period20212022202320242025
Sales, quarterly000000000
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q2 '24Q2 '25
Shares, annual5.2285.2282.1430.7242.293
Period20212022202320242025
Shares, quarterly5.2285.2285.2285.2285.2281.4681.4067.270.3
PeriodQ4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q2 '24Q2 '25

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.000.000.000.00
Gross Profit-0.01-0.01-0.00-0.000.000.00
Selling, General and Administrative Excl. Other6.236.233.662.751.290.33
Research and Development1.471.470.340.95--
Other Operating Expense0.000.000.000.000.000.00
Operating Income-6.24-6.24-3.66-2.75-1.29-0.33
Non-Operating Income (Expense)-0.95-0.950.090.883.550.00
Interest Expense0.010.010.010.050.000.00
Unusual Expense-0.30-0.30-4.6049.23-5.76-8.56
Net Income Before Taxes-6.89-6.891.01-51.168.018.23
Income Taxes0.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Consolidated Net Income-6.94-6.941.01-51.168.018.23
Net Income From Continuing Operations-6.94-6.941.01-51.168.018.23
Net Income-6.94-6.941.01-51.168.018.23
EPS (Recurring)-12.94-12.94-3.04-16.010.760.43
EPS (Basic, Before Extraordinaries)-12.56-12.561.40-49.061.531.57
EPS (Diluted)-12.56-12.561.40-49.061.531.57
EBITDA-6.23-6.23-3.66-2.75-1.29-0.33
Stock Option Compensation Expense0.160.160.000.32--
Shares Outstanding0.302.290.722.145.235.23
Market Capitalization11.5611.56217.275,988.475,988.47-

Income statement, quarterly

Currency USD, millions
Metric2025Q22024Q22023Q22023Q22023Q12022Q42022Q32022Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit-0.00-0.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other1.501.160.560.510.770.510.160.29
Research and Development0.360.27------
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.51-1.16-0.56-0.51-0.77-0.51-0.16-0.29
Interest Expense0.000.00---0.000.000.00
Unusual Expense-0.68-1.300.26-0.26-0.26-0.13-0.13-2.22
Net Income Before Taxes-0.750.14-0.65-0.06-0.022.250.772.04
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-0.750.14-0.65-0.06-0.022.250.772.04
Net Income From Continuing Operations-0.750.14-0.65-0.06-0.022.250.772.04
Net Income-0.750.14-0.65-0.06-0.022.250.772.04
EPS (Recurring)-5.19-0.23-0.38-0.19-0.110.410.150.11
EPS (Basic, Before Extraordinaries)-3.180.04-0.53-0.05-0.010.430.170.45
EPS (Diluted)-3.180.04-0.53-0.05-0.010.430.170.45
EBITDA-1.50-1.16-0.56-0.51-0.77-0.51-0.16-0.29
Non-Operating Income (Expense)0.070.000.170.190.492.630.800.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.00------
Shares Outstanding0.307.271.411.471.475.235.235.23
Market Capitalization11.562,715.90568.38-----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments7.496.170.760.130.65
Short Term Receivables0.360.140.040.830.00
Inventories0.000.000.000.000.00
Other Current Assets1.260.250.320.250.32
Total Current Assets9.116.561.131.210.97
Net Property, Plant & Equipment0.010.010.010.000.00
Total Investments and Advances8.450.740.00257.73255.00
Intangible Assets0.000.000.000.000.00
Other Assets0.000.000.000.000.25
Total Assets17.577.321.13258.93256.22
Short Term Debt Incl. Current Port. of LT Debt0.000.007.660.000.00
Accounts Payable0.000.000.000.000.00
Other Current Liabilities0.620.594.4514.270.07
Total Current Liabilities0.620.5912.1014.270.07
Long Term Debt0.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.0019.51
Total Liabilities0.620.5912.1014.2719.58
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity16.946.72-10.97244.66236.65
Total Shareholders Equity16.946.72-10.97244.66236.65
Accumulated Minority Interest0.000.000.000.000.00
Total Equity16.946.72-10.97244.66236.65
Total Liabilities & Stockholders Equity17.577.321.13258.93256.22
Book Value Per Share7.399.28-5.1246.8045.27
Tangible Book Value Per Share7.399.28-5.1246.8045.27
Full-Time Employees12121033
Price to Book Ratio0.08-173.11-1,712.53-1,712.53-
Return on Assets-55.7523.95-39.343.11-
Return on Equity-58.62--43.783.33-
Return on Invested Capital-40.9415.05-3.283.48
Quick Ratio14.6211.040.090.0814.17
Current Ratio14.6211.040.090.0814.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-6.94-6.941.01-51.168.018.23
Depreciation0.010.010.000.00--
Deferred Taxes & Investment Tax Credit0.000.000.000.000.000.00
Other Funds (Non Cash)0.000.00-4.3649.39-8.48-8.56
Funds from Operations-6.93-6.93-3.35-1.77-0.47-0.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.22-1.22-0.39-1.17-0.05-0.50
Cash from Operating Activities-8.14-8.14-3.73-2.95-0.52-0.84
Capital Expenditures-0.00-0.00-0.01-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-4.50-4.500.000.000.00-255.00
Purchase of Investments-4.50-4.500.000.000.00-255.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-4.50-4.50-0.01-0.010.00-255.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock13.9613.968.150.000.00256.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock13.9613.968.150.000.00256.49
Proceedsfrom Stock Options13.9613.968.150.000.00256.49
Issuance or Reduction of Debt, Net-0.01-0.010.992.350.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities13.9513.959.152.350.00256.49
Net Change in Cash1.311.315.40-0.60-0.520.65
Free Cash Flow-8.14-8.14-3.74-2.95-0.52-0.84

Balance sheet, quarterly

Currency USD, millions
Metric2025Q22024Q22023Q22023Q22023Q12022Q4
Cash & Short Term Investments7.201.960.090.010.020.13
Short Term Receivables0.170.130.050.070.060.83
Inventories0.000.000.000.000.000.00
Other Current Assets0.260.160.020.100.210.25
Total Current Assets7.632.240.160.180.291.21
Net Property, Plant & Equipment0.010.010.000.000.000.00
Total Investments and Advances5.170.0012.5216.5416.12257.73
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets12.812.2512.6816.7316.40258.93
Short Term Debt Incl. Current Port. of LT Debt0.000.051.611.180.690.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities0.943.4614.5714.0914.1914.27
Total Current Liabilities0.943.5116.1815.2614.8814.27
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.943.5116.1815.2614.8814.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity11.87-1.26-3.501.461.52244.66
Total Shareholders Equity11.87-1.26-3.501.461.52244.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.87-1.26-3.501.461.52244.66
Total Liabilities & Stockholders Equity12.812.2512.6816.7316.40258.93
Book Value Per Share39.62-0.17-2.491.001.0446.80
Tangible Book Value Per Share39.62-0.17-2.491.001.0446.80
Full-Time Employees-----3
Price to Book Ratio0.08-2,163.88-162.54---
Return on Assets--1.132.153.703.11
Return on Equity--1.272.414.183.33
Return on Invested Capital-6.35---4.30-1.610.92
Quick Ratio8.090.640.010.010.020.08
Current Ratio8.090.640.010.010.020.08

Cash flow, quarterly

Currency USD, millions
Metric2025Q22024Q22023Q22023Q22023Q12022Q4
Net Income---0.65-0.06-0.022.25
Other Funds (Non Cash)--0.090.32-1.51-1.93
Funds from Operations---0.560.26-1.540.32
Extraordinary Item--0.000.000.000.00
Changes in Working Capital--0.31-0.510.99-0.40
Cash from Operating Activities---0.25-0.25-0.55-0.09
Capital Expenditures--0.000.000.000.00
Net Assets From Acquisitions--0.000.000.000.00
Sale of Fixed Assets and Businesses--0.000.000.000.00
Purchase or Sale of Investments--4.21-0.25242.860.00
Purchase of Investments---0.10-0.25-0.250.00
Sale Or Maturity of Investments--4.310.00243.110.00
Other Uses--0.000.000.000.00
Other Sources--0.000.000.000.00
Cash from Investing Activities--4.21-0.25242.860.00
Cash Dividends Paid--0.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock---4.310.00-243.110.00
Repurchase of Common Pref Stock---4.310.00-243.110.00
Sale of Common Pref Stock--0.000.000.000.00
Proceedsfrom Stock Options--0.000.000.000.00
Issuance or Reduction of Debt, Net--0.000.000.000.00
Change in Long Term Debt--0.000.000.000.00
Issuance of Long Term Debt--0.000.000.000.00
Reduction of Long Term Debt--0.000.000.000.00
Net Financing Active Other Cash Flow--0.430.490.690.00
Other Financing Activities Uses--0.000.000.000.00
Cash from Financing Activities---3.880.49-242.430.00
Net Change in Cash--0.08-0.01-0.11-0.09
Free Cash Flow---0.25-0.25-0.55-0.09

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.80%0.0M1.1M78.18K
2026-10-151.91%0.0M1.1M88.89K
2026-09-301.05%0.0M2.6M92.01K
2026-09-151.88%0.0M2.6M80.68K
2026-08-310.54%0.0M2.6M86.55K
2026-08-140.56%0.0M2.6M77.97K
2026-07-311.46%0.0M2.6M110.26K
2026-07-151.20%0.0M2.6M2.63M
2026-06-3014.40%0.0M0.3M2.58M
2026-06-1513.42%0.0M0.3M2.54M
2026-05-2910.40%0.0M0.3M2.56M
2026-05-1528.51%0.1M0.3M2.61M
2026-04-3016.66%0.0M0.3M2.72M
2026-04-1517.26%0.0M0.3M205.44K
2026-03-3120.22%0.1M0.3M209.49K
2026-03-1329.51%0.1M0.3M311.62K
2026-02-2756.83%0.1M0.3M350.85K
2026-02-1334.69%0.1M0.3M342.63K
2026-01-309.31%0.0M0.3M240.24K
2026-01-1526.93%0.0M0.0M218.17K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-15SCHEDULE 13D/ASEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-10-05SCHEDULE 13GSEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-28SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-23SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-01EFFECTEffectiveness filing by commission orderSEC
2026-08-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-26F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-06-2220-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2026-03-31SEC
2026-06-10SCHEDULE 13G/ASEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-06-03SCHEDULE 13DSEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-23SEC
2026-04-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-20SEC
2026-04-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-17SEC
2026-04-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-03-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-02SEC
2026-02-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-19SEC
2026-02-19SCHEDULE 13GSEC
2026-02-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-19SEC
2026-02-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-13SEC
2026-02-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-12SEC
2026-01-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-29SEC
2026-01-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-27SEC
2026-01-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-14SEC
2026-01-13SCHEDULE 13D/ASEC
2026-01-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY12.62%
JANE STREET GROUP, LLC10.16%
AdvisorShares Investments LLC6.78%
XTX Topco Ltd5.04%
Parallel Advisors, LLC3.97%
CITADEL ADVISORS LLC3.90%
Stonehage Fleming Financial Services Holdings Ltd0.03%
Caitlin John, LLC0.01%
UBS Group AG0.01%

Funds

Fund% owned
AdvisorShares Psychedelics ETF40.80%

OakChart. PBM. Cached 15 minutes.

Some panels did not load: ratings, insider.